Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Auclin

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 30, 2021
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapyIthar Gataa, Laura Mezquita, Caroline Rossoni, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2023
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)Constance Thibault, Aude Fléchon, Laurence Albiges, et al.
British Journal of Cancer|March 27, 2021
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohortEdouard Auclin, Lysiane Marthey, Raef Abdallah, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System ProgressionMihaela Aldea, Lizza Hendriks, Laura Mezquita, et al.
Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
Cancers|August 7, 2021
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient TumorsEdouard Auclin, Perrine Vuagnat, Cristina Smolenschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerKathryn C Arbour, Laura Mezquita, Niamh Long, et al.
Journal of Oncology|February 28, 2022
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter StudyCharles Vauchier, Edouard Auclin, Philippe Barthélémy, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|January 30, 2021
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapyIthar Gataa, Laura Mezquita, Caroline Rossoni, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2023
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)Constance Thibault, Aude Fléchon, Laurence Albiges, et al.
British Journal of Cancer|March 27, 2021
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohortEdouard Auclin, Lysiane Marthey, Raef Abdallah, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System ProgressionMihaela Aldea, Lizza Hendriks, Laura Mezquita, et al.
Cell Reports. Medicine|November 18, 2020
CD103<sup>+</sup>CD8<sup>+</sup> T<sub>RM</sub> Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17Stéphanie Corgnac, Ines Malenica, Laura Mezquita, et al.
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
Cancers|August 7, 2021
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient TumorsEdouard Auclin, Perrine Vuagnat, Cristina Smolenschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerKathryn C Arbour, Laura Mezquita, Niamh Long, et al.
Journal of Oncology|February 28, 2022
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter StudyCharles Vauchier, Edouard Auclin, Philippe Barthélémy, et al.
British Journal of Cancer|December 15, 2023
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world studyClémence Flecchia, Edouard Auclin, Emily Alouani, et al.
Pageof 9